Invest KOREA

PharmCADD is an AI & Physics-based drug discovery company in South Korea. Since its establishment in March 2019, PharmCADD has focused on R&D and developed a comprehensive technology platform, covering small molecules (‘Pharmulator’), DDS/RNA (‘PharmVAC’), PROTAC (‘PharmTAC’) and ADME/T (‘PharmKineTox’). PharmCADD has 36 R&D staff and 17 of them have Ph.Ds. 
Our technology has been validated in the market by multiple licensed out contracts with major domestic pharmaceutical companies. In particular, our AI-assisted mRNA COVID-19 vaccine is currently under global clinical trial phase 2a. For now, we have 10+ pipelines across anti-cancer, autism, blood anticoagulant and COVID-19 treatment projects. 
PhamCADD has established PharmCADD USA. with a view to accessing talent, securing investment capital and seeking new business opportunities. At the current stage, we are open to developing partnerships both on the parent company (PharmCADD) level and the US subsidiary (PharmCADD USA) level, depending on the need and fit of the counterparties. I would love to have a chance to discuss you with the potential opportunities and benefits of collaboration between our two institutions. Thank you